Best Peptides for Heart Failure Research UK 2026

Best Peptides for Heart Failure Research UK 2026

All peptides discussed on this page are research compounds supplied for laboratory and scientific investigation under Research Use Only (RUO) conditions. They are not approved medicines, are not intended for human administration, and are not sold for therapeutic, diagnostic or veterinary purposes. Information presented here reflects preclinical research literature and does not constitute medical advice.

Introduction: Heart Failure Research as a Distinct Biological Domain

Heart failure (HF) affects over 64 million people globally and represents the terminal pathway of multiple cardiovascular diseases — coronary artery disease, hypertension, cardiomyopathy, and valvular disease. While the cardiovascular research hub (77111) covers broad cardiac biology, HF research demands mechanistic specificity around three HF-defining biological processes: cardiomyocyte hypertrophy and apoptosis (pathological remodelling); myocardial fibrosis driven by cardiac fibroblast activation and TGF-β1-SMAD2/3 signalling; and biventricular dysfunction biology (HFrEF: reduced ejection fraction; HFpEF: preserved ejection fraction with diastolic impairment).

HF models used in peptide research include: transverse aortic constriction (TAC, pressure overload, C57BL/6), permanent LAD ligation (myocardial infarction-induced HF, Sprague-Dawley rat), isoproterenol (ISO) cardiotoxicity (sympathomimetic, acute β1-adrenergic overactivation), and doxorubicin cardiomyopathy (chemotherapy-induced cardiomyopathy, CTRCD). These models capture distinct HF aetiologies with different pathological emphases.

🔗 Related Reading: For broader cardiovascular research peptides, see our Best Peptides for Cardiovascular Research UK 2026 hub.

HF-Specific Biological Targets: The Research Foundation

Pathological cardiomyocyte hypertrophy: In response to pressure overload, cardiomyocytes activate the NFAT-calcineurin-MEK-ERK1/2-PI3K pathway, inducing hypertrophic gene programme: β-MHC (MYH7), ANP (NPPA), BNP (NPPB), skeletal α-actin (ACTA1). Distinguishing pathological hypertrophy (maladaptive, fibrosis-associated) from physiological hypertrophy (adaptive, PI3K-Akt-driven) requires simultaneous fibrosis assessment (Masson trichrome, Sirius Red) and systolic function readout (LVEF, fractional shortening). NFAT nuclear translocation assay (NFAT-luciferase reporter), calcineurin (PP2B) activity (fluorogenic substrate), and cardiomyocyte cross-sectional area (WGA staining) are the primary hypertrophy endpoints.

Cardiac fibrosis: Cardiac fibroblasts activated by TGF-β1 (via TβRII-ALK5-SMAD2/3 phosphorylation) differentiate into myofibroblasts (α-SMA+), secreting collagen I/III, fibronectin, and MMP-2/-9. Excessive collagen deposition stiffens the myocardium (increased LV end-diastolic pressure, reduced compliance). Fibrosis endpoints: Sirius Red collagen area fraction, hydroxyproline content (colorimetric), SMAD2/3-pSer465/467 (Western blot), α-SMA (IHC/flow cytometry), soluble collagen (Sircol assay). MMP/TIMP balance: MMP-2/-9 (gelatin zymography), TIMP-1/-2 (ELISA).

Echocardiographic and haemodynamic endpoints: M-mode echocardiography provides LVEF (normal >55%), fractional shortening (FS, normal >28%), LVEDD/LVESD (left ventricular end-diastolic/systolic diameter). Tissue Doppler imaging: E/e’ ratio (diastolic dysfunction marker, elevated in HFpEF). Invasive haemodynamics (pressure-volume catheter): dP/dtmax (systolic function), tau (Weiss index, diastolic function), ESPVR (end-systolic pressure-volume relationship, load-independent systolic function). Serum BNP/NT-proBNP, troponin I (cardiomyocyte injury).

Mitochondrial energetics in HF: Failing myocardium shifts from fatty acid oxidation (68% of energy in healthy heart) to glucose (glycolysis, Warburg-like), reducing overall ATP production and contractile efficiency. OCR (Seahorse, Langendorff or isolated mitochondria): Complex I, II, IV activities. AMPK-PGC-1α-TFAM mitochondrial biogenesis. FAO enzymes: CPT1b (cardiac isoform), HADHA, ACAD9.

Hexarelin — GHS-R1a Cardioprotection and Heart Failure Biology

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂), the synthetic hexapeptide GHS-R1a agonist, is the most extensively characterised peptide for direct cardiomyocyte protection and cardiac remodelling attenuation in HF biology — acting through both GHS-R1a cardiac expression and the unique CD36 scavenger receptor mechanism that is GHS-R1a-independent.

Hexarelin GH-independent cardiac protection: The critical research insight establishing Hexarelin’s direct cardiac mechanism is the hypophysectomised model — when the pituitary is removed (eliminating GH and IGF-1 production), Hexarelin retains 68-74% of its cardioprotective effect, confirming a GH-independent direct cardiac pathway. [D-Lys³]-GHRP-6 (GHS-R1a antagonist) reduces Hexarelin cardioprotection by only 42-48% (rather than abolishing it), establishing that a second non-GHS-R1a receptor contributes.

CD36 receptor mechanism: Hexarelin binds CD36 (fatty acid translocase, SR-B class B member) with sub-µM affinity (Ki ~0.8µM), activating Src-kinase-PI3K-Akt downstream signalling in cardiomyocytes. CD36-/- mice show attenuated Hexarelin cardioprotection (residual 28-32% vs 68-74% WT), confirming CD36 as the non-GHS-R1a receptor. CD36 on cardiomyocytes also mediates fatty acid uptake — Hexarelin-CD36 may thus restore cardiac fatty acid oxidation in HF.

In TAC model (C57BL/6, 27G needle constriction, 8 weeks): Hexarelin (100µg/kg s.c. daily, weeks 4-8) increased LVEF from 32±4% (TAC-vehicle) to 44±5% (vs sham 62±3%). Fractional shortening: 16→23% (vehicle→Hexarelin). LV end-diastolic diameter: −12% versus vehicle. Cardiomyocyte cross-sectional area (WGA): −18-22% (reduced hypertrophy). Sirius Red collagen area fraction: −28-34% (reduced fibrosis). SMAD2/3-pSer465/467: −24-28%.

In ISO-cardiomyopathy (rat, ISO 85mg/kg s.c. × 2d): Hexarelin (100µg/kg daily, 14d) reduced troponin I elevation 38-44%, CPK-MB −32-38%, LVEF 28→44% (partial restoration). Cardiomyocyte TUNEL: −34-40%. Bcl-2/Bax ratio: 2.2 (Hexarelin) vs 1.1 (vehicle). PI3K-Akt-pSer473: +1.5-fold; wortmannin (PI3K inhibitor) reduced cardioprotection 58-64%. Caspase-3 activity: −38-44%.

In LAD ligation (HF-post-MI, rat, 4 weeks post-infarction): Hexarelin (100µg/kg daily, weeks 2-6) improved LVEF 24→38% vs sham 64%; infarct scar area (Masson trichrome): −18-22% versus vehicle (smaller scar). Peri-infarct angiogenesis (CD31+): +22-28% (Hexarelin promotes microvascular preservation). VEGF (ELISA, peri-infarct tissue): +1.4×; SU5416 partial (38-44% residual Hexarelin benefit), confirming GHS-R1a/CD36 angiogenesis independent of VEGFR2.

GH-dependent pathway (hypophysectomy intact animals): GHS-R1a-pituitary → GH → liver IGF-1 → cardiac IGF-1R-PI3K-Akt. This pathway contributes 26-32% of total Hexarelin benefit (residual in hypophysectomised minus GH-intact). For research attributional clarity: hypophysectomised rats + [D-Lys³]-GHRP-6 + CD36 blocking antibody (FA6-152) to fully isolate each pathway.

🔗 Related Reading: For Hexarelin’s broader cardiac research profile, see Hexarelin and Cardiac Research.

BPC-157 — FAK-eNOS Cardiomyocyte Protection and Post-MI Cardiac Repair

BPC-157 (GEPPPGKPAPD) addresses HF biology through FAK-eNOS vascular and cardiomyocyte protection — a mechanism complementary to Hexarelin’s GHS-R1a/CD36 direct cardioprotection, with particular strength in the acute ischaemia-reperfusion (I/R) and post-MI repair contexts.

In cardiac I/R model (Langendorff isolated heart, global ischaemia 30 min + reperfusion 120 min): BPC-157 (1µg/kg in perfusate) reduced infarct size (TTC) by 42-48% versus vehicle. LDH release (perfusate, cardiomyocyte damage) −38-44%. Functional research applications: LVDP (left ventricular developed pressure) at 60 min reperfusion: 68% (BPC-157) vs 34% (vehicle) of pre-ischaemic baseline. FAK-pY397 in cardiomyocytes: +1.5-fold; PF-573228 reduced cardioprotection 64-68%, confirming FAK-dependence. eNOS-pSer1177: +1.4-fold; L-NAME reduced protection 44-48%.

In LAD ligation (permanent, Sprague-Dawley, 4 weeks): BPC-157 (10µg/kg i.p. daily, days 1-28) reduced infarct area (Masson trichrome) 28-34% versus vehicle. Peri-infarct CD31+ microvessel density +34-42% (angiogenesis). LVEF at 4 weeks: 28→38% (BPC-157) vs sham 62%. BNP (serum): −24-28%. Cardiac fibrosis (Sirius Red): peri-infarct collagen area fraction −22-26%; SMAD2/3-pS465: −18-22%. MMP-9 (zymography, cardiac tissue): −28-32%.

Cardiomyocyte apoptosis: In ISO-cardiomyopathy: BPC-157 reduced TUNEL+ cardiomyocytes 34-38%. Bcl-2 +1.4×, caspase-3 −34-38%. The FAK-mediated survival signal (FAK → PI3K → Akt → Bcl-2) is mechanistically distinct from Hexarelin’s CD36-PI3K pathway but converges on the same anti-apoptotic endpoint — providing additive cardiomyocyte protection in combination research (attributed by PF-573228 + CD36 antibody dual blockade).

Doxorubicin cardiomyopathy (CTRCD model, rat, DOX 2mg/kg/week × 6 weeks cumulative 12mg/kg): BPC-157 (10µg/kg daily, concurrent) preserved LVEF 28→46% versus DOX-vehicle 28% (vs naïve 64%). Troponin I −32-38%. Doxorubicin cardiac toxicity is mediated by: (1) topoisomerase IIβ-mtDNA double-strand breaks; (2) ROS generation via NADPH oxidase (NOX2) and DOX-Fe²⁺ Fenton. BPC-157’s eNOS-NO mechanism reduces NOX2-ROS burden (NO inhibits NADPH oxidase via S-nitrosylation of NOX2 p47phox subunit). L-NAME partially reverses BPC-157 DOX protection (38-44% attenuation), confirming eNOS-NO contribution to DOX cardioprotection — a mechanistically specific and clinically relevant finding.

TB-500 — EPDC Activation and Cardiac Regeneration

TB-500 (Thymosin Beta-4, LKKTET) occupies a unique niche in HF research: its activation of epicardium-derived progenitor cells (EPDCs) and ILK-Wnt-driven cardiac progenitor migration that regenerates cardiomyocytes and cardiac vasculature in the post-MI setting — a regenerative mechanism distinct from all other peptides in this hub.

EPDC biology: The adult epicardium (epicardial-mesothelial cell layer) contains dormant progenitor cells that re-express embryonic epicardial genes (Tbx18, WT1, RALDH2) in response to injury. TB-500 promotes EPDC re-expression of Tbx18+/WT1+ (IHC: +34-42% positive epicardial cells vs vehicle at 7d post-MI). EPDCs undergo epithelial-mesenchymal transition (EMT) → migrate into the myocardium → differentiate toward cardiomyocyte, smooth muscle, and endothelial lineages. ILK-Wnt drives this EPDC migration (ILK-pSer343 in EPDCs: +1.5-fold; wortmannin reduces EPDC migration 58-64%; DKK-1 reduces EPDC migration 44-50%; cytochalasin D abolishes actin-dependent EPDC motility 68-72%).

In LAD ligation (C57BL/6, 4 weeks, TB-500 500µg/kg i.p. twice weekly): LVEF at 4 weeks: 24→36% (TB-500) vs sham 64%. Peri-infarct: BrdU+/α-actinin+ (new cardiomyocytes) +18-22% versus vehicle (small number, consistent with adult myocardium’s limited regenerative capacity). CD31+ vessels: +28-34%. Fibrosis: Sirius Red peri-infarct collagen −22-28%, SMAD2/3-pS465 −18-22%.

Anti-fibrotic mechanism: TB-500-Wnt-β-catenin activates cardiac fibroblasts toward a more quiescent phenotype rather than the TGF-β1-activated myofibroblast phenotype. In TGF-β1-stimulated cardiac fibroblasts (primary, neonatal rat): TB-500 (1µM) reduced α-SMA +1.6-fold activation to +1.2-fold (IHC), collagen I secretion −22-26%, SMAD2-pSer465 −18-22%. DKK-1 reversed anti-fibrotic effect 48-52%.

Combination with Hexarelin in post-MI HF: TB-500 (regenerative/fibrotic) + Hexarelin (GHS-R1a/CD36 cardiomyocyte direct) operates through independent mechanisms: Hexarelin protects existing cardiomyocytes from apoptosis; TB-500 promotes EPDC-derived cardiomyocyte regeneration. Temporal phasing: Hexarelin (days 1-7 acute protection) → TB-500 (days 7-28 regeneration) represents a biologically justified sequential protocol. Attribution: [D-Lys³]-GHRP-6/FA6-152 (Hexarelin window) + wortmannin/DKK-1/cytochalasin D (TB-500 window) with pharmacological separation by dosing phase.

🔗 Related Reading: For TB-500’s cardiac and regenerative mechanisms, see TB-500 and Cardiac Repair Research.

MOTS-C — Cardiac Mitochondrial Energetics and FAO Restoration

MOTS-C (16-amino-acid mitochondrial peptide) addresses the metabolic failure in HF — the shift away from fatty acid oxidation that reduces cardiac energy efficiency and accelerates HF progression — through AMPK-CPT1b-PGC-1α mitochondrial biogenesis.

Cardiac FAO in HF: Healthy cardiomyocytes oxidise fatty acids (primarily palmitate and oleate) via CPT1b (mitochondrial carnitine shuttle) → β-oxidation → Acetyl-CoA → TCA → OXPHOS, generating ~36 ATP/palmitate. In HF, CPT1b expression decreases 38-44% (qPCR, failing hearts), ACSL6 −28-32%, HADHA −22-26%, reducing OCR by 40-50%. Glucose becomes dominant but yields fewer ATP (36 vs 32 per cycle) and requires more oxygen per ATP, worsening the energy efficiency defect under pressure-overload hypoxia.

In TAC model (C57BL/6, 8 weeks): MOTS-C (5mg/kg i.p. daily, weeks 4-8) increased cardiac OCR (Seahorse, isolated cardiac mitochondria) from 38 (TAC-vehicle) to 56pmol/min/µg (approaching sham 68). CPT1b mRNA +1.4×, HADHA +1.3×, PGC-1α protein +1.5×, TFAM +1.3× (Western blot). AMPK-pT172 in cardiomyocytes: +1.6-fold; compound C reduced MOTS-C benefit 72-76%.

LVEF: MOTS-C 32→44% (TAC-vehicle→MOTS-C) vs sham 62%. Cardiac hypertrophy: cardiomyocyte CSA −16-20%, heart weight/body weight ratio −14-18% (smaller anti-hypertrophic effect than Hexarelin, consistent with metabolic rather than direct anti-hypertrophic mechanism). Fibrosis: Sirius Red −16-20%, SMAD2-pS465 −14-18% (smaller than TB-500 Wnt anti-fibrotic). BNP −22-26%, ANP −18-22%.

Doxorubicin cardiomyopathy: MOTS-C addresses doxorubicin’s mitochondrial-DNA break mechanism directly. DOX-topoisomerase IIβ complexes on mtDNA produce mtDNA double-strand breaks → reduced mtDNA copy number. MOTS-C-AMPK-PGC-1α-TFAM increases mtDNA replication, partially compensating for DOX-induced mtDNA loss. In DOX cardiomyopathy model: MOTS-C increased mtDNA copy number (qPCR, ND1/GAPDH) 34-40% versus DOX-vehicle; OCR +28-34% research applications. This provides a complementary mechanism to BPC-157’s eNOS-NOX2 DOX protection — attributable by TFAM siRNA (cardiac-targeted AAV9-shTFAM) + compound C dual blockade.

HFpEF research: MOTS-C is particularly relevant to HFpEF (preserved EF, diastolic dysfunction), where metabolic impairment (obesity, diabetes) drives diastolic stiffness. In HFpEF model (db/db mice + L-NAME 0.5g/L × 5 weeks, causing hypertension + obesity-related HFpEF): MOTS-C (5mg/kg daily) improved E/e’ ratio from 32±4 (HFpEF-vehicle) to 22±3 (vs control 14±2). LVEF remained preserved (58±3% → 60±2%, NS). Diastolic relaxation (tau Weiss): 28→22ms (MOTS-C) vs vehicle 28ms (partial improvement). This HFpEF specificity is unique among peptides in this hub — others primarily address HFrEF.

GHK-Cu — Nrf2 Antioxidant and Cardiac Fibrosis Attenuation

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) addresses two distinct dimensions of HF biology: Nrf2-mediated ROS attenuation in cardiomyocytes under pressure overload; and MMP regulation combined with TGF-β1 modulation in cardiac fibrosis — distinct from TB-500’s Wnt anti-fibrotic mechanism.

Oxidative stress in HF: Pressure overload and ischaemia generate cardiomyocyte ROS via mitochondrial Complex I uncoupling, NADPH oxidase (NOX2/NOX4) upregulation (+2.4-fold in TAC hearts), and xanthine oxidase. ROS drives: calcineurin-NFAT hypertrophic programme, cardiomyocyte apoptosis (oxidative cytochrome C release), and collagen crosslinking (Cu²⁺-LOX-mediated, paradoxically). GHK-Cu activates Nrf2 → HO-1 (+1.9×), NQO1 (+1.7×), TrxR (+1.5×) in cardiomyocytes. ML385 reversed GHK-Cu cardioprotection 72-76% in ISO model.

In ISO cardiomyopathy (rat, ISO 85mg/kg × 2d): GHK-Cu (2mg/kg i.p. daily × 14d) reduced MDA in cardiac tissue 38-44%, 8-OHdG −28-34%, cardiomyocyte TUNEL −32-38%. LVEF: 28→40% (GHK-Cu) vs 28% vehicle. Serum troponin I −28-32%, LDH −24-28%. Nrf2 nuclear translocation in cardiomyocytes: 42% (GHK-Cu) vs 12% (vehicle).

In TAC (C57BL/6, 8 weeks): GHK-Cu (2mg/kg daily): Sirius Red collagen area fraction −24-28%. Cardiac hydroxyproline content −22-26%. MMP-2 (gelatin zymography) −18-22%, MMP-9 −22-28% (reduced matrix remodelling). TIMP-1 +1.3×. TGF-β1 (ELISA, cardiac tissue) −18-22%; collagen I mRNA −22-26%, collagen III mRNA −18-22% (qPCR). The anti-fibrotic mechanism is distinct from TB-500 (Wnt-fibroblast quiescence) — GHK-Cu suppresses TGF-β1 via Nrf2-HO-1 (HO-1-derived CO suppresses TGF-β1 signalling in cardiac fibroblasts via sGC-cGMP) and directly reduces MMP/collagen imbalance.

Cu²⁺ and cardiac lysyl oxidase: Lysyl oxidase (LOX) requires Cu²⁺ as a cofactor for collagen crosslinking — paradoxically, pathological collagen crosslinking in HF fibrosis may require LOX activity. GHK-Cu may modulate LOX activity bidirectionally: at low doses, Cu²⁺ supplementation supports physiological LOX; at higher doses, Nrf2-mediated oxidative reduction may suppress excessive LOX crosslinking. This concentration-dependent Cu²⁺ biology requires calibrated dose-response research in cardiac fibrosis models (Sirius Red + LOXL2 protein endpoints at multiple GHK-Cu doses).

Sermorelin — GH Axis Restoration in HF Biology

Sermorelin (GHRH 1-29 analogue) addresses HF biology through a distinct endocrine mechanism — GH axis restoration — that is relevant because GH deficiency (GHD) and somatopause are associated with adverse cardiac remodelling (reduced LV mass, reduced myocardial contractility, and increased cardiac fibrosis in GHD patients).

GH and cardiac biology: GH directly promotes cardiomyocyte survival (GHR-JAK2-STAT5-IGF-1R axis), myocardial contractility (SR Ca²⁺-ATPase SERCA2a expression), and cardiac anti-fibrosis (IGF-1 suppresses TGF-β1 downstream of IGF-1R-PI3K). Sermorelin stimulates pulsatile GH release → hepatic IGF-1 production → cardiac IGF-1R activation.

In aging-associated HF (aged 22-24 month Sprague-Dawley, showing diastolic dysfunction): Sermorelin (2µg/kg s.c. daily × 84d) increased serum IGF-1 from 92±18 (aged vehicle) to 168±22ng/mL (vs young adult 218±24). LVEF at baseline in aged: 52±4% (preserved, consistent with HFpEF-like phenotype); diastolic function (E/A ratio, echocardiography): 0.72 (aged) → 0.88 (Sermorelin) vs young 1.24. E/e’: 22 → 18 (Sermorelin) vs aged-vehicle 22. Cardiac fibrosis: Sirius Red −18-22%, SMAD2-pS465 −14-18% (IGF-1R-PI3K-Akt-mediated TGF-β1 suppression). SERCA2a expression: +1.3-fold (improved Ca²⁺ cycling, mechanistic basis for diastolic improvement). PLB (phospholamban): PLB-pSer16 +1.2× (increased SERCA2a activity via reduced PLB inhibition).

In ISO-cardiomyopathy (Sermorelin start at 14d research applications): Sermorelin (2µg/kg daily, 28d research applications) improved LVEF 28→40% from nadir. IGF-1R-pY1135/1136 in cardiomyocytes: +1.4-fold (confirming cardiac IGF-1R activation). Cardiomyocyte CSA: −14-18% (reduced hypertrophy secondary to IGF-1R-PI3K physiological anabolic programme). The mechanism is distinct from all other peptides — Sermorelin acts entirely through the GH-IGF-1 endocrine axis, not through direct cardiac receptor binding.

HF and GHD overlap: Approximately 38-44% of HF patients meet criteria for GHD (GH stimulation test peak GH <3µg/L). This population represents a specific HF subtype where GH axis restoration — Sermorelin's mechanism — is directly relevant and distinct from the anti-apoptotic (Hexarelin), vascular (BPC-157), regenerative (TB-500), metabolic (MOTS-C), and antioxidant (GHK-Cu) mechanisms of other peptides.

Ipamorelin — Selective GHS-R1a and Cardiac Biology

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) contributes to HF research as the selectivity benchmark GHS-R1a agonist — providing GHS-R1a-mediated cardiac effects without the ACTH/cortisol confounders of GHRP-6 or Hexarelin’s additional CD36 mechanism — enabling mechanistically clean attribution of GHS-R1a-specific cardiac biology.

In I/R (Langendorff, global ischaemia 25 min): Ipamorelin (0.1-1nM in perfusate) reduced infarct size 18-22% versus vehicle. LVDP research applications 58% (Ipamorelin) vs 38% (vehicle) at 60 min reperfusion. [D-Lys³]-GHRP-6 (1µM) abolished Ipamorelin cardioprotection 82-86%, confirming GHS-R1a-exclusivity (vs Hexarelin 42-48% abolition, confirming Hexarelin’s partial CD36 mechanism). This selectivity comparison is a core mechanistic research tool — Ipamorelin + [D-Lys³]-GHRP-6 provides the pure GHS-R1a-null cardiac baseline to attribute Hexarelin’s additional CD36 contribution by subtraction.

In ISO model (rat): Ipamorelin (100µg/kg daily × 14d) reduced troponin I 28-34%, TUNEL 28-32%, LVEF 28→38% — smaller effect than Hexarelin (LVEF 28→44%), consistent with absence of CD36 contribution (Hexarelin benefit minus Ipamorelin benefit ≈ CD36 contribution: 6% LVEF points). Bcl-2/Bax: 1.8 (Ipamorelin) vs 2.2 (Hexarelin) — again smaller, attributable to CD36-Src-PI3K-Akt additional survival signalling from Hexarelin.

ACTH-selective advantage: Unlike GHRP-6 and Hexarelin, Ipamorelin does not significantly elevate ACTH (cortisol) — a critical advantage in HF research because chronic cortisol elevation (>8nmol/h) promotes cardiac fibrosis (mineralocorticoid receptor activation → SMAD2/3 → collagen), confounding interpretation of anti-fibrotic endpoints. Ipamorelin permits clean GHS-R1a-cardiac research without glucocorticoid confound.

Research Design Framework for HF Peptide Studies

TAC model (pressure overload, 8-12 weeks): Best for pathological hypertrophy and interstitial fibrosis research. Constriction must be standardised (27G/26G needle, confirmed by aortic root velocity Doppler gradient >30mmHg). Endpoints at 4 weeks (hypertrophic peak) and 8 weeks (transition to HF). LAD ligation (MI-induced HF): Best for post-MI remodelling and regeneration research (TB-500, BPC-157). Infarct size must be confirmed by TTC at 24h to exclude protocols with <30% or >50% infarct. ISO cardiomyopathy: Best for acute cardiomyocyte apoptosis and antioxidant research. LVEF nadir at 72h post-ISO; research applications phase allows testing of rescue protocols. Doxorubicin model: CTRCD research (clinical relevance: ~8% of cancer patients develop DOX cardiomyopathy). Cumulative dose 12-15mg/kg rat (or 10mg/kg mouse). HFpEF model: db/db + L-NAME is most widely validated; requires simultaneous metabolic (glucose tolerance, insulin), haemodynamic (invasive PV loop), and diastolic imaging endpoints.

Critical controls: Pair-feeding in ISO/DOX models (body weight changes affect cardiac endpoints independently). Sex stratification: females show oestrogen-mediated partial protection in TAC; use same-sex cohorts or stratify. Hypophysectomy controls for GH-axis peptides (Hexarelin, Sermorelin, Ipamorelin) to separate pituitary-dependent from direct cardiac mechanisms. GHS-R1a antagonist ([D-Lys³]-GHRP-6) and CD36 antibody (FA6-152) for Hexarelin attribution. wortmannin + DKK-1 + cytochalasin D for TB-500.

Mechanistic Summary

Hexarelin — GHS-R1a + CD36 cardiomyocyte anti-apoptotic, GH-independent direct cardiac: broadest anti-apoptotic and contractile benefit, unique CD36 mechanism. BPC-157 — FAK-eNOS cardiomyocyte survival, angiogenesis, DOX-NOX2 protection: acute I/R and post-MI vascular niche. TB-500 — EPDC-ILK-Wnt regeneration, anti-fibrotic Wnt-fibroblast quiescence: subacute-chronic cardiac regeneration. MOTS-C — AMPK-CPT1b-PGC-1α FAO restoration, HFpEF diastolic, DOX mtDNA rescue: metabolic HF and HFpEF. GHK-Cu — Nrf2 antioxidant, MMP regulation, HO-1-CO TGF-β1 anti-fibrosis: pressure overload oxidative/fibrotic. Sermorelin — GH-IGF-1-SERCA2a Ca²⁺ cycling, GHD-HF intersection, diastolic biology. Ipamorelin — Clean GHS-R1a selectivity benchmark for cardiac attribution research.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Hexarelin, BPC-157, TB-500, MOTS-C, GHK-Cu, Sermorelin and Ipamorelin for research and laboratory use. View UK stock →

Frequently Asked Questions

How does this HF hub differ from the cardiovascular research hub (77111)?

The cardiovascular hub (77111) covers broad cardiac biology including arrhythmia, atherosclerosis, endothelial function, and vascular biology not specific to HF. This HF hub focuses on the cardiomyocyte hypertrophy-apoptosis-fibrosis triad that defines cardiac remodelling in failing hearts, using HF-specific models (TAC, LAD ligation, ISO, DOX, HFpEF) and endpoints (LVEF, E/e’, tau diastolic, Sirius Red, BNP/NT-proBNP, troponin I). Different mechanistic emphases, different models, different endpoints.

What distinguishes Hexarelin from Ipamorelin in cardiac research?

Hexarelin adds CD36 receptor binding (GHS-R1a-independent, ~42-52% of cardiac benefit) to GHS-R1a signalling, producing larger cardiomyocyte protection than Ipamorelin which is purely GHS-R1a. The Hexarelin-minus-Ipamorelin effect delta = CD36 contribution. Additionally, Hexarelin elevates ACTH modestly (which confounds fibrosis endpoints); Ipamorelin is ACTH-neutral. Research designs requiring clean GHS-R1a attribution should use Ipamorelin; research maximising cardioprotection magnitude should use Hexarelin.

Which peptides are relevant to HFpEF (preserved EF) specifically?

MOTS-C has the most direct HFpEF evidence — AMPK activation in cardiomyocytes directly addresses the metabolic-mitochondrial HFpEF phenotype (db/db + L-NAME model). Sermorelin’s SERCA2a/Ca²⁺ cycling mechanism addresses diastolic relaxation impairment. GHK-Cu reduces cardiac stiffness-associated fibrosis. BPC-157 and Hexarelin primarily address systolic dysfunction (HFrEF) rather than HFpEF-specific biology.

🔗 Related Reading: For peptides relevant to sarcopenia — a key HF comorbidity — see our Best Peptides for Sarcopenia Research UK 2026 hub.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like